Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A study combining two drugs, Daratumumab and Lenalidomide as Maintenance Therapy for Patients with Multiple Myeloma

Research Question:
Does treating multiple myeloma patients with two drugs Daratumumab and Lenalidomide help them become negative for the disease?

Basic Study Information

Purpose:
Patients will be treated with Daratumumab and Lenalidomide or Lenalidomide alone for two years and then tested for minimal residual disease. Minimal residual disease is the evidence for the presence of residual malignant cells, even when so few cancer cells are present that they cannot be found by routine means. In a patient who has been treated, the detection of MRD indicates that treatment is incomplete. MRD can thus distinguish who needs intensive and potentially more toxic therapy from those who do not. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be either continue or discontinue the assigned treatment. Patients are treated for up to 7 years and followed for up to 15 years.

Location: University of Rochester Medical Center
Study Reference #: CMMY19113

Lead Researcher (Principal Investigator)

Lead Researcher: Brea Lipe

Study Contact Information

Study Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Email: Kaitlyn_Burrows@URMC.Rochester.edu

Additional Study Details

Return to Search